The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis

被引:0
作者
Richard Charles John Campbell
Michael Batley
Anthony Hammond
Fowzia Ibrahim
Gabrielle Kingsley
David L. Scott
机构
[1] King’s College London School of Medicine,Department of Rheumatology
[2] Weston Education Centre,Department of Rheumatology
[3] Maidstone Hospital,undefined
来源
Clinical Rheumatology | 2012年 / 31卷
关键词
Anti-TNF; DAS28; Disease modifying anti-rheumatic drugs; Fatigue; Rheumatoid arthritis;
D O I
暂无
中图分类号
学科分类号
摘要
We investigate a range of clinical factors and anti-rheumatic treatments, for their degree of association with rheumatoid arthritis (RA) fatigue in 557 patients. A range of clinical measures concerning disability, pain and disease activity together with drug history were recorded as part of routine clinical visits. Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT-F) questionnaire. Spearman's correlation (p < 0.05) evaluated FACIT-F against the other clinical measures. Mean FACIT-F was compared between the treatment groups. Multivariate linear regression analysis investigated association between the clinical measures and FACIT-F in more detail. Correlation (p < 0.05) with FACIT-F was the strongest for Health Assessment Questionnaire (HAQ) (r = −0.68), patient global (r = −0.64) and pain (r = −0.62) visual analogue scores. In multivariate models, DAS28, HAQ and pain explained variability in fatigue the best (R2 = 0.54). Further analyses, looking at the sub components of DAS28, show that fatigue is mainly associated with tender joint counts and pain rather than swollen joint counts or erythrocyte sedimentation rate. RA fatigue levels were not significantly different between patients on no treatment, disease modifying anti-rheumatic drugs or biologics. Fatigue in established RA is not specifically influenced by the type of treatment used but is associated with tender joint counts, pain and disability. This finding is in contrast to recent trials in early RA that suggest biologics are better than traditional disease modifying anti-rheumatic drugs for fatigue. This difference in result may be because the origins of fatigue are not the same in early compared with established RA.
引用
收藏
页码:717 / 722
页数:5
相关论文
共 180 条
[1]  
Wolfe F(1996)The prevalence and meaning of fatigue in rheumatic disease J Rheumatol 23 1407-846
[2]  
Hawley DJ(1981)Preliminary criteria for clinical remission in rheumatoid arthritis Arthritis Rheum 24 1308-575
[3]  
Wilson K(1993)Correlates of fatigue in older adults with rheumatoid arthritis Nurs Res 42 93-2199
[4]  
Pinals RS(2003)Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status Rheumatology (Oxford) 42 995-1167
[5]  
Masi AT(2000)Fatigue in chronic disease Clin Sci 99 1-1450
[6]  
Larsen RA(2007)Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis J Rheumatol 34 1171-undefined
[7]  
Belza BL(2005)Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis J Rheumatol 32 811-undefined
[8]  
Henke CJ(2003)Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 30 2563-undefined
[9]  
Yelin EH(2006)Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multi-center, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793-undefined
[10]  
Epstein WV(2008)Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 987-undefined